Journal
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
Volume 8, Issue 7, Pages 710-716Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/187152008785914770
Keywords
Serine/threonine kinase; inhibitor; RSK specific
Categories
Funding
- U. S. Army Medical Research and Material Command Research Plan [02-43U-057, Y3-CM-100505]
- National Cancer Institute, National Institutes of Health [N01-CO-12400]
- Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis of the National Cancer Institute
Ask authors/readers for more resources
Ribosomal S6 kinase (RSK) is a family of serine/threonine kinases that has been identified as a promising anti-cancer target. While a number of protein kinase inhibitors that have potent activity against other serine/threonine kinases were shown to also inactivate RSK, there is keen interest in the three different inhibitor chemotypes that were shown to be RSK specific, since these compounds have tremendous utility as chemical probes in elucidating the biochemistry of the RSK signaling cascade and unraveling the molecular basis of cancer. Because each compound may have therapeutic potential, the nonspecific kinase inhibitors as well as the RSK specific inhibitors will be discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available